|
Phase 1 of ABTL0812, a proautophagic drug, in combination with paclitaxel and carboplatin at first-line in advanced endometrial cancer and squamous cell lung carcinoma. |
|
|
Consulting or Advisory Role - Tesaro |
|
Purificación Estévez-García |
Consulting or Advisory Role - Clovis Oncology; Tesaro |
Speakers' Bureau - AstraZeneca; PharmaMar; Roche |
Research Funding - AstraZeneca; MSD |
Expert Testimony - AstraZeneca |
Travel, Accommodations, Expenses - MSD; PharmaMar; Roche |
|
Jose Alejandro Perez-Fidalgo |
Speakers' Bureau - AstraZeneca Spain; Ipsen; Novartis; Pfizer; PharmaMar; Roche |
Travel, Accommodations, Expenses - AstraZeneca; Pfizer; Roche |
|
|
Consulting or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb; MSD; Pierre Fabre; Roche |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Ability Pharma; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; MSD; Pfizer; Roche; Takeda |
Research Funding - Pfizer (Inst); Roche (Inst); Roche (Inst) |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Lilly; MSD; Pfizer; Roche |
|
Victor Rodriguez Freixinos |
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Expert Testimony - Mundipharma; Novartis; Roche |
Travel, Accommodations, Expenses - Roche |
|
|
Consulting or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb |
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Roche |
Travel, Accommodations, Expenses - Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Roche |
|
|
Travel, Accommodations, Expenses - Roche |
|
Maria Pilar Barretina-Ginesta |
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; Roche; Tesaro |
Travel, Accommodations, Expenses - PharmaMar; Roche; Tesaro |
|
|
Consulting or Advisory Role - Roche; Tesaro |
Travel, Accommodations, Expenses - Pfizer |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Boehringer Ingelheim; Ellipses Pharma; Janssen; NeoMed; Roche |
|
Research Funding - Novartis |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Glycotope GmbH; Glycotope GmbH; Menarini |
|
|
Honoraria - Lilly; Novartis; Orion; Peptor; SERVIER |
Consulting or Advisory Role - Lilly; Novartis; Orion; Peptor; SERVIER |
Research Funding - Bayer; Novartis |
|
|
Stock and Other Ownership Interests - Ability Pharma |
Patents, Royalties, Other Intellectual Property - Ability Pharma |
|
|
Employment - Ability Pharma |
Leadership - Ability Pharma |
Stock and Other Ownership Interests - Ability Pharma |
Honoraria - Ability Pharma |
Research Funding - Ability Pharma |
Patents, Royalties, Other Intellectual Property - Ability Pharma |
Travel, Accommodations, Expenses - Ability Pharma |
|
|
Employment - Ability Pharma |
Stock and Other Ownership Interests - Ability Pharma |
Honoraria - Ability Pharma |
Research Funding - Ability Pharma |
Patents, Royalties, Other Intellectual Property - Ability Pharma |
Travel, Accommodations, Expenses - Ability Pharma |
|
|
Employment - Vall d'Hebron University Hospital Institute of Oncology |
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; ImmunoGen; PharmaMar; Roche; Tesaro |
Travel, Accommodations, Expenses - AstraZeneca; Clovis Oncology; PharmaMar; Roche; Tesaro |